The Pattern of Use of Oral NSAIDs with or without Coprescription of Gastroprotective Agent for Arthritic Knee by Korean Practitioners
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Th e aim of this study was to describe the patterns of use of non-steroidal anti-infl ammatory drugs (NSAIDs) for arthritic knees in clinical practice, particularly focusing on the co-prescription of gastroprotective agents for patients with risk factors for adverse gastrointestinal (GI) events. Materials and Methods: Each cross-sectional cohort was a group of outpatients visiting 111 physicians who had prescribed NSAIDs for the patients’arthritic knees for more than three consecutive months. A self-administered questionnaire was completed by each patient and physician. Results: Nine hundred and forty fi ve patients (48%) of the whole 1,960 patients belonged to the group with a high or very high risk for NSAIDinduced gastropathy determined by northern California Health Maintenance Organization guidelines. Overall, only less than half of the patients were given co-prescription of gastroprotective agents, regardless of the presence or absence of GI symptoms and irrespective of the level of risk for NSAIDinduced gastropathy. Conclusions: Th e physician prescribing NSAIDs for arthritic knees should monitor any GI symptoms and the patient monitor anylevel for NSAIDinduced gastropathy, and be willing to add gastroprotective agents as necessary in order to prevent serious adverse GI events.
Abstract
Purpose: Th e aim of this study was to describe the patterns of use of non-steroidal anti-infl ammatory drugs (NSAIDs) for arthritic knees in clinical practice, particularly focusing on the co-prescription of gastroprotective agents for patients with risk factors for adverse gastrointestinal (GI) events. Materials and Methods: Each cross-sectional cohort was a group of outpatients visiting 111 physicians who had prescribed NSAIDs for the patients’arthritic knees for more than three consecutive months. A self-administered questionnaire was completed by each patient and physician. Results: Nine hundred and forty fi ve patients (48%) of the whole 1,960 patients belonged to the group with a high or very high risk for NSAIDinduced gastropathy determined by northern California Health Maintenance Organization guidelines. Overall, only less than half of the patients were given co-prescription of gastroprotective agents, regardless of the presence or absence of GI symptoms and irrespective of the level of risk for NSAIDinduced gastropathy. Conclusions: Th e physician prescribing NSAIDs for arthritic knees should monitor any GI symptoms and the patient monitor anylevel for NSAIDinduced gastropathy, and be willing to add gastroprotective agents as necessary in order to prevent serious adverse GI events.
참고문헌 (17)
- Fries JF, "Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models", Am J Med, 91, pp.213~222 (1991)
- Lanas A, "NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention", Chin J Dig Dis, 7, pp.127~133 (2006)
- Zhang W, "OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines", Osteoarthritis Cartilage, 16, pp.137~162 (2008)
- Richmond J, "American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee (nonarthroplasty)", J Am Acad Orthop Surg, 17, pp.591~600 (2009)
- Korean Knee Society Subcommittee on Osteoarthritis Guidelines, "Guidelines for the treatment of osteoarthritis of the knee", J Korean Knee Soc, 22, pp.69~74 (2010)
- Lanas A, "Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study", Ann Rheum Dis, 69, pp.1453~1458 (2010)
- Huang JQ, "Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis", Lancet, 359, pp.14~22 (2002)
- Graham DY, "NSAIDs, risks, and gastroprotective strategies: current status and future", Gastroenterology, 134, pp.1240~1246 (2008)
- Bull SA, "Relationship of clinical factors to the use of Cox-2 selective NSAIDs within an arthritis population in a large HMO", J Manag Care Pharm, 8, pp.252~258 (2002)
- Wolfe MM, "Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs", N Engl J Med, 340, pp.1888~1899 (1999)
- Graham DY, "NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-infl ammatory drugs: results of a double-blind, randomized, multicenter, active- and placebocontrolled study of misoprostol vs lansoprazole", Arch Intern Med, 162, pp.169~175 (2002)
- Chan FK, "Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding", N Engl J Med, 352, pp.238~244 (2005)
- Silverstein FE, "Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial", Ann Intern Med, 123, pp.241~249 (1995)
- Stockl K, "Gastrointestinal bleeding rates among managed care patients newly started on cox- 2 inhibitors or nonselective NSAIDs", J Manag Care Pharm, 11, pp.550~558 (2005)
- Rich M, "Nonsteroidal anti-inflammatory drug gastropathy at the new millennium: mechanisms and prevention", Semin Arthritis Rheum, 30, pp.167~179 (2000)
- Inoue N, "Th e enantiomers of etodolac, a racemic anti-infl ammatory agent, play diff erent roles in effi cacy and gastrointestinal safety", Biol Pharm Bull, 34, pp.655~659 (2011)
- Arakawa T, "Rebamipide: overview of its mechanisms of action and effi cacy in mucosal protection and ulcer healing", Dig Dis Sci, 43(9), pp.5S~13S (1998)